Results 1 to 10 of about 117,284 (247)
The role of JAK2 abnormalities in hematologic neoplasms. [PDF]
Hematology Reports, 2009 In 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Mohammed Khalid Alabdulaali
doaj +4 more sources
Autoimmune Complications in Hematologic Neoplasms [PDF]
Cancers, 2021 Autoimmune cytopenias (AICy) and autoimmune diseases (AID) can complicate both lymphoid and myeloid neoplasms, and often represent a diagnostic and therapeutic challenge. While autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) are well known, other rarer AICy (autoimmune neutropenia, aplastic anemia, and pure red cell aplasia) and ...
Barcellini W. +2 more
core +5 more sources
Hematological Neoplasms with Eosinophilia
Cancers, 2023 Eosinophils in peripheral blood account for 0.3–5% of leukocytes, which is equivalent to 0.05–0.5 × 109/L. A count above 0.5 × 109/L is considered to indicate eosinophilia, while a count equal to or above 1.5 × 109/L is defined as hypereosinophilia. In bone marrow aspirate, eosinophilia is considered when eosinophils make up more than 6% of the total ...
Rosario M. Morales-Camacho +4 more
openaire +6 more sources
Cell Communication and Signaling, 2023 In clinical diagnosis, the capability of exosomes to serve as biomarkers is one of the most important biological functions of exosomes. The superior stability of exosome biomarkers makes them superior to those isolated from traditional samples such as ...
Faride Nam Avar Jahromi +2 more
doaj +2 more sources
Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH
Clinical and Translational Oncology, 2021 20.500.12530/87854Venous thromboembolism (VTE) is a serious complication in hematologic neoplasms, so finding adequate prevention strategies is an urgent requirement.
Pascual Marco +2 more
exaly +2 more sources
GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE [PDF]
Mediterranean Journal of Hematology and Infectious Diseases, 2023 Advances in molecular biology and genetic testing have greatly improved our understanding of the genetic basis of hematologic malignancies and have enabled the identification of new cancer predisposition syndromes. The recognition of a germline mutation
Francesco Fabozzi, Angela Mastronuzzi
doaj +2 more sources
Quality of life and functional capacity during the treatment of hematologic neoplasms [PDF]
Fisioterapia em Movimento, 2018 Introduction: Cancer is a serious pathology with a high incidence and complex diagnoses. Emotional and environmental factors, the deleterious effects of these, and lifestyle affect different outcomes.
Monique Vanderlinde de Souza +3 more
doaj +3 more sources
A potential prognostic marker for hematologic neoplasms: CD58
Frontiers in OncologyCD58 is a glycoprotein receptor widely distributed on histiocytes that binds to CD2, that takes part in constituting the Immunological Synapses (IS) and activating T/NK cells.
Ningning Yue, Jiajia Cao
exaly +3 more sources
EBF1, PAX5, and MYC: regulation on B cell development and association with hematologic neoplasms [PDF]
Frontiers in ImmunologyDuring lymphocyte development, a diverse repertoire of lymphocyte antigen receptors is produced to battle against pathogens, which is the basis of adaptive immunity.
Daiquan Zhang, Xinmei Cao, Li Li
exaly +2 more sources
Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer
Cancers, 2019 An indirect consequence of the improved long-term survival seen in patients with breast cancer (BC) is the increased risk of hematologic malignant neoplasms (HM).
Norbert Vey +2 more
exaly +2 more sources